분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-10-03 23:23:20 , Hit : 554
 Nonviral CRISPR Delivery a Success

The Scientist »
News & Opinion »
Daily News


http://www.the-scientist.com/?articles.view/articleNo/50546/title/Nonviral-CRISPR-Delivery-a-Success/&utm_campaign=NEWSLETTER_TS_The-Scientist-Daily_2016&utm_source=hs_email&utm_medium=email&utm_content=56948738&_hsenc=p2ANqtz-_X85RDYVA3gVzHKWAHFRsVizMDrdTvWpyj3XP_3GmZ1UhY-XZ6tJmek88PK7yH5YFBtXEorUaNWXlg58i42vNEQEmJUg&_hsmi=56948738


Researchers use gold nanoparticles to deliver CRISPR-Cas9 and correct a point mutation in a mouse model of Duchenne muscular dystrophy.

By Abby Olena | October 2, 2017



AddThis Sharing Buttons
Share to FacebookShare to TwitterShare to RedditShare to 이메일Share to 더 보기




Muscle from a mouse model of Duchenne muscular dystrophy. Fibrous scar tissue is in blue and healthy muscle is in pink.

CONBOY LAB AND MURTHY LAB
While promising, applications of CRISPR-Cas9 gene editing have so far been limited by the challenges of delivery—namely, how to get all the CRISPR parts to every cell that needs them.  In a study published today (October 2) in Nature Biomedical Engineering, researchers have successfully repaired a mutation in the gene for dystrophin in a mouse model of Duchenne muscular dystrophy by injecting a vehicle they call CRISPR-Gold, which contains the Cas9 protein, guide RNA, and donor DNA, all wrapped around a tiny gold ball.

The authors have made “great progress in the gene editing area,” says Tufts University biomedical engineer Qiaobing Xu, who did not participate in the work but penned an accompanying commentary. Because their approach is nonviral, Xu explains, it will minimize the potential off-target effects that result from constant Cas9 activity, which occurs when users deliver the Cas9 template with a viral vector.

Duchenne muscular dystrophy is a degenerative disease of the muscles caused by a lack of the protein dystrophin. In about a third of patients, the gene for dystrophin has small deletions or single base mutations that render it nonfunctional, which makes this gene an excellent candidate for gene editing. Researchers have previously used viral delivery of CRISPR-Cas9 components to delete the mutated exon and achieve clinical improvements in mouse models of the disease.

See “CRISPR Correct Duchenne-Causing Mutations”

“In this paper, we were actually able to correct [the gene for] dystrophin back to the wild-type sequence” via homology-directed repair (HDR), coauthor Niren Murthy, a drug delivery researcher at the University of California, Berkeley, tells The Scientist. “The other way of treating this is to do something called exon skipping, which is where you delete some of the exons and you can get dystrophin to be produced, but it’s not [as functional as] the wild-type protein.”

The research team created CRISPR-Gold by covering a central gold nanoparticle with DNA that they modified so it would stick to the particle. This gold-conjugated DNA bound the donor DNA needed for HDR, which the Cas9 protein and guide RNA bound to in turn. They coated the entire complex with a polymer that seems to trigger endocytosis and then facilitate escape of the Cas9 protein, guide RNA, and template DNA from endosomes within cells.

In order to do HDR, “you have to provide the cell [with] the Cas9 enzyme, guide RNA by which you target Cas9 to a particular part of the genome, and a big chunk of DNA, which will be used as a template to edit the mutant sequence to wild-type,” explains coauthor Irina Conboy, who studies tissue repair at the University of California, Berkeley. “They all have to be present at the same time and at the same place, so in our system you have a nanoparticle which simultaneously delivers all of those three key components in their active state.”


They coated the entire CRISPR-Gold complex with a polymer that seems to trigger endocytosis and then facilitate escape of the Cas9 protein, guide RNA, and template DNA from endosomes within cells.

Conboy, Murthy, and colleagues found that CRISPR-Gold induced HDR in targeted genes in vitro in a variety of cell types, including human embryonic stem cells and mouse muscle cells. They then tested CRISPR-Gold HDR efficiency in vivo by injecting it into the muscles of a mouse model for Duchenne muscular dystrophy that does not produce dystrophin. A single dose of CRISPR-Gold restored dystrophin levels two weeks after injection and corrected the relevant point mutation to the wild-type sequence in about 5 percent of the copies of the gene for dystrophin in injected muscles. Injection of the Cas9 protein, guide RNA, and donor DNA without the particles corrected less than 1 percent of the copies of the gene for dystrophin. Muscle function also improved in mice treated with CRISPR-Gold.

This work “is a big step forward for biomedical application of CRISPR,” says Vincent Rotello, a drug delivery and nanotechnology researcher at the University of Massachusetts at Amherst who did not participate in the work. “There are some applications where a localized injection like this makes sense,” he adds, but “one of the challenges with the [CRISPR-Gold] system is it doesn’t have systemic delivery.”

“Ideally, you would inject into the bloodstream because then the particles could go into every single muscle,” agrees Conboy. She and Murthy continue to investigate ways to improve delivery and editing efficiency, both for Duchenne muscular dystrophy and other genetic diseases.

Two of the paper’s other authors, Kunwoo Lee and Hyo Min Park, founded a company called Genedit to explore commercial applications of CRISPR-Gold. “We’re certainly very excited about the therapeutic possibilities of delivering the Cas9 protein,” says Murthy, who serves as a scientific advisor.

“There’s a lot of work to be done to move to the point where we’ll actually be able to cure diseases,” says Rotello, “but I think this shows the way forward.”

K. Lee et al., “Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair,” Nature Biomedical Engineering, doi:10.1038/s41551-017-0137-2, 2017.







1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 587
1226   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 589
1225   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 531
1224   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 836
1223   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 508
1222   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1006
1221   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 510
1220   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 368
1219   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 489
1218   CRISPR/Cas9 Edits Epigenome with Therapeutic Efficiency  이성욱 2017/12/09 484
1217   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 685
1216   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 566
1215   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 607
1214   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 663
1213   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 639
  Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 554
1211   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 498
1210   To Speed CRISPR/Cas9’s Search and Snip, Try Extra Cas9 and gRNA  이성욱 2017/09/30 1988
1209   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 502
1208   Mutations Making CRISPR Hyper-Accurate Discovered  이성욱 2017/09/22 850

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN